$SURG
SurgePays, Inc. Stock $surg

$surg Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018890 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$15.09M	$31.43M	$34.78M
YoY Change	-57.96%	-9.63%	64.49%
Cost Of Revenue	$18.53M	$23.25M	$27.08M
YoY Change	-28.35%	-14.16%	46.33%
Gross Profit	-$3.443M	$8.183M	$7.694M
YoY Change	-134.34%	6.34%	192.16%
Gross Profit Margin	-22.82%	26.04%	22.13%
Selling, General & Admin	$7.433M	$6.431M	$2.989M
YoY Change	94.42%	115.12%	-14.9%
% of Gross Profit		78.59%	38.85%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$70.38K	$70.38K	$70.38K
YoY Change	0.0%	0.0%	-58.86%
% of Gross Profit		0.86%	0.91%
Operating Expenses	$7.433M	$6.431M	$2.989M
YoY Change	94.42%	115.12%	-18.85%
Operating Profit	-$10.88M	$1.752M	$4.705M
YoY Change	-275.35%	-62.77%	-548.04%
Interest Expense	-$99.01K	-$116.4K	$400.0K
YoY Change	-33.99%	-129.11%	-305.31%
% of Operating Profit		-6.65%	8.5%
Other Income/Expense, Net	$537.9K	-$116.4K	-$159.3K
YoY Change	-469.52%	-26.91%
Pretax Income	-$10.34M	$1.635M	$4.546M
YoY Change	-270.6%	-64.02%	-465.13%
Income Tax	$2.547M	$423.0K
% Of Pretax Income		25.86%
Net Earnings	-$12.87M	$1.225M	$4.546M
YoY Change	-315.65%	-73.06%	-475.01%
Net Earnings / Revenue	-85.28%	3.9%	13.07%
Basic Earnings Per Share	-$0.66	$0.07	$0.32
Diluted Earnings Per Share	-$0.66	$0.07	$0.31
COMMON SHARES
Basic Shares Outstanding	19.41M shares	19.29M shares	14.12M shares
Diluted Shares Outstanding	19.43M shares	18.68M shares	14.54M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.43M	$42.95M	$8.862M
YoY Change	640.55%	384.59%	157.4%
Cash & Equivalents	$38.43M	$42.95M	$8.862M
Short-Term Investments
Other Short-Term Assets	$507.9K	$499.9K	$170.0K
YoY Change	198.78%	194.15%	-29.01%
Inventory	$8.363M	$7.344M	$15.52M
Prepaid Expenses	$507.9K	$499.9K	$170.0K
Receivables	$1.412M	$8.272M	$9.660M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$48.72M	$59.06M	$34.21M
YoY Change	44.43%	72.62%	175.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$221.1K	$291.5K	$573.0K
YoY Change	-56.01%	-49.13%	-14.08%
Goodwill	$4.167M	$4.167M	$1.667M
YoY Change	149.99%	149.99%
Intangibles	$1.800M	$1.963M	$2.617M
YoY Change	-26.64%	-24.98%
Long-Term Investments	$498.3K	$480.6K	$387.2K
YoY Change	24.57%	24.1%	-7.38%
Other Assets	$0.00	$2.542M
YoY Change
Total Long-Term Assets	$7.687M	$10.52M	$6.353M
YoY Change	23.76%	65.66%	17.68%
TOTAL ASSETS
Total Short-Term Assets	$48.72M	$59.06M	$34.21M
Total Long-Term Assets	$7.687M	$10.52M	$6.353M
Total Assets	$56.41M	$69.59M	$40.57M
YoY Change	41.21%	71.53%	127.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.797M	$7.070M	$7.609M
YoY Change	-18.55%	-7.07%	8.47%
Accrued Expenses	$96.33K	$94.24K	$40.38K
YoY Change	140.83%	133.38%	9.52%
Deferred Revenue
YoY Change
Short-Term Debt	$1.607M	$1.567M	$2.240M
YoY Change	39.71%	-30.02%	44.73%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.600M	$9.432M	$25.65M
YoY Change	-64.27%	-63.22%	187.63%
LONG-TERM LIABILITIES
Long-Term Debt	$3.206M	$3.625M	$4.550M
YoY Change	-29.08%	-20.32%	-25.41%
Other Long-Term Liabilities	$317.5K	$342.4K	$389.0K
YoY Change	-16.46%	-11.96%	-9.4%
Total Long-Term Liabilities	$3.523M	$3.968M	$4.939M
YoY Change	-28.14%	-19.66%	-24.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.600M	$9.432M	$25.65M
Total Long-Term Liabilities	$3.523M	$3.968M	$4.939M
Total Liabilities	$10.12M	$13.40M	$30.59M
YoY Change	-56.7%	-56.19%	98.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.83M	-$13.96M	-$31.26M
YoY Change	6.07%	-55.33%
Common Stock	$19.44K	$19.44K	$14.18K
YoY Change	36.04%	37.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.16M	$56.04M	$9.854M
YoY Change
Total Liabilities & Shareholders Equity	$56.41M	$69.59M	$40.57M
YoY Change	41.21%	71.53%	127.89%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$12.87M	$1.225M	$4.546M
YoY Change	-315.65%	-73.06%	-475.01%
Depreciation, Depletion And Amortization	$70.38K	$70.38K	$70.38K
YoY Change	0.0%	0.0%	-58.86%
Cash From Operating Activities	-$4.130M	$4.040M	$2.866M
YoY Change	55.86%	40.98%	-186.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$157.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00		-$157.0K
YoY Change	-100.0%		1277.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$2.870K
YoY Change
Cash From Financing Activities	-380.3K	$24.28M	-$882.3K
YoY Change	-58.21%	-2852.17%	-278.47%
NET CHANGE
Cash From Operating Activities	-4.130M	$4.040M	$2.866M
Cash From Investing Activities	0.000		-$157.0K
Cash From Financing Activities	-380.3K	$24.28M	-$882.3K
Net Change In Cash	-4.511M	$28.32M	$1.826M
YoY Change	22.57%	1450.73%	-164.3%
FREE CASH FLOW
Cash From Operating Activities	-$4.130M	$4.040M	$2.866M
Capital Expenditures
Free Cash Flow			$2.866M
YoY Change			-186.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001392694
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	SURG	Stock Issued During Period Value Exercise Of Warrants Cashless StockIssuedDuringPeriodValueExerciseOfWarrantsCashless		usd
CY2023Q1	SURG	Recognition Of Stock Based Compensation Unvested Shares Related Party RecognitionOfStockBasedCompensationUnvestedSharesRelatedParty		usd
CY2023Q1	SURG	Interest Expene Adjustment Sba Loans InterestExpeneAdjustmentSbaLoans		usd
CY2023Q1	SURG	Rightofuse Asset Lease Payment Adjustment True Up RightofuseAssetLeasePaymentAdjustmentTrueUp		usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
CY2024Q1	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet		usd
CY2024Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	SURG	Reclassification Of Sba Note Payable Government To Note Payable ReclassificationOfSbaNotePayableGovernmentToNotePayable		usd
CY2023Q1	SURG	Exercise Of Warrants Cashless ExerciseOfWarrantsCashless		usd
CY2023Q1	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability		usd
CY2023Q1	SURG	Supplemental Disclosure Of Non Cash Investing And Financing Activities Goodwill SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesGoodwill		usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet		usd
CY2024Q1	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions		usd
CY2023Q1	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableNumber		shares
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageExercisePrice
CY2024Q1	us-gaap	Cash Cash	42945078	usd
CY2023Q4	us-gaap	Cash Cash	14622060	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8271878	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9536074	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	7343739	usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2024Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023Q4	SURG	Installment Sale Liability InstallmentSaleLiability		usd
CY2023Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2024Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023Q1	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	SURG	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40992
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	SURGEPAYS, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0550352
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3124 Brother Blvd
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 104
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bartlett
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	38133
CY2024Q1	dei	City Area Code CityAreaCode	901
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	302-9587
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19411549	shares
CY2023Q4	us-gaap	Inventory Net InventoryNet	9046594	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	499908	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161933	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	59060603	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33366661	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	291458	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361841	usd
CY2024Q1	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1963093	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2126470	usd
CY2024Q1	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	483717	usd
CY2023Q4	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	539424	usd
CY2024Q1	us-gaap	Goodwill Goodwill	4166782	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2024Q1	us-gaap	Investments Investments	480562	usd
CY2023Q4	us-gaap	Investments Investments	464409	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	420107	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	387869	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2542000	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2835000	usd
CY2024Q1	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	10233112	usd
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	8196805	usd
CY2024Q1	us-gaap	Assets Assets	69585173	usd
CY2023Q4	us-gaap	Assets Assets	41925307	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	700000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	570000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	20000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94244	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43137	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9431948	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12705044	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	342444	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	356276	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3967726	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	816799	usd
CY2024Q1	us-gaap	Liabilities Liabilities	13399674	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13521843	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19431549	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19431549	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14403261	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14403261	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	19435	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	14404	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69985592	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43421019	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13961608	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15186203	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	56043419	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28249220	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	142080	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	154244	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	56185499	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	69585173	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41925307	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	23246468	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	27081960	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6430806	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2989421	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	29677274	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	30071381	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1751861	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4705062	usd
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	132583	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	192326	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	16153	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	33029	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-116430	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-159297	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1635431	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4545765	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	423000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1212431	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4545765	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12164	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-576	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1224595	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17693283	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14131276	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18678136	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14535222	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2024Q1	SURG	Stock Issued During Period Value New Issues Stock Issued For Cash StockIssuedDuringPeriodValueNewIssuesStockIssuedForCash	17249994	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-1395000	usd
CY2024Q1	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	8799257	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	411740	usd
CY2024Q1	SURG	Adjustments To Additional Paid In Capital Share Based Compensation Unvested Shares Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationUnvestedSharesRequisiteServicePeriodRecognition	1497417	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6196	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12164	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1224595	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	56185499	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	307458	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-576	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9980770	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9980770	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1212431	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4545765	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	233760	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	233758	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	23363	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10687	usd
CY2024Q1	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	55707	usd
CY2023Q1	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	32265	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	411740	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	307458	usd
CY2024Q1	SURG	Recognition Of Stock Based Compensation Unvested Shares Related Party RecognitionOfStockBasedCompensationUnvestedSharesRelatedParty	1497417	usd
CY2024Q1	SURG	Interest Expene Adjustment Sba Loans InterestExpeneAdjustmentSbaLoans	19750	usd
CY2024Q1	SURG	Rightofuse Asset Lease Payment Adjustment True Up RightofuseAssetLeasePaymentAdjustmentTrueUp	46338	usd
CY2024Q1	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16153	usd
CY2023Q1	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	33029	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1264196	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	429187	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1702855	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4335727	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	337975	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	58428	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-293000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	130000	usd
CY2023Q1	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet	2026713	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	470211	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	28012	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9548	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4040058	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2865796	usd
CY2023Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	157044	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157044	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17249994	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	8799257	usd
CY2024Q1	SURG	Cash Paid As Direct Offering Costs CashPaidAsDirectOfferingCosts	1395000	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	368421	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	467385	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	410468	usd
CY2024Q1	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	2870	usd
CY2023Q1	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	4468	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24282960	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-882321	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28323018	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1826431	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14622060	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7035654	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42945078	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8862085	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	129003	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	100074	usd
CY2024Q1	SURG	Reclassification Of Sba Note Payable Government To Note Payable ReclassificationOfSbaNotePayableGovernmentToNotePayable	498991	usd
CY2024Q1	SURG	Exercise Of Warrants Cashless ExerciseOfWarrantsCashless	41	usd
CY2024Q1	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability	98638	usd
CY2024Q1	SURG	Supplemental Disclosure Of Non Cash Investing And Financing Activities Goodwill SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesGoodwill	2500000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1224595	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4040058	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13961608	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	56185499	usd
CY2024Q1	SURG	Working Capital WorkingCapital	49628655	usd
CY2024Q1	us-gaap	Cash Cash	42945078	usd
CY2024Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	2500000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	98638	usd
CY2024Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	2500000	usd
CY2024Q1	SURG	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Fair Value Of Consideration Transferred BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationTransferred	2500000	usd
CY2024Q1	SURG	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Operating Lease BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseOperatingLease	98638	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	98638	usd
CY2024Q1	SURG	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Right Of Use Operating Lease BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRightOfUseOperatingLease	98638	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	98638	usd
CY2024Q1	us-gaap	Goodwill Goodwill	2500000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	4166782	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2024Q1	SURG	Notes Receivable Gross Due Remainder Of Fiscal Year NotesReceivableGrossDueRemainderOfFiscalYear	141759	usd
CY2024Q1	SURG	Notes Receivable Gross Due In Next Twelve Months NotesReceivableGrossDueInNextTwelveMonths	44766	usd
CY2024Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	186525	usd
CY2024Q1	SURG	Less Interest Receivable LessInterestReceivable	9674	usd
CY2024Q1	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2023	us-gaap	Payments To Acquire Other Receivables PaymentsToAcquireOtherReceivables	52227	usd
CY2024Q1	SURG	Payments To Acquire Additional Receivables PaymentsToAcquireAdditionalReceivables	22383	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9046594	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zUznB75caD6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zUL218jsXOZc">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the three months ended March 31, 2024 and 2023, respectively, include, allowance for doubtful accounts and other receivables, inventory reserves and classifications, valuation of loss contingencies, valuation of stock-based compensation, estimated useful lives related to intangible assets, capitalized internal-use software development costs, and property and equipment, implicit interest rate in right-of-use operating leases, uncertain tax positions, income tax payable and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SURGEPAYS, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MARCH 31, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	17525	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	17525	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	7343739	usd
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2024Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2024Q1	SURG	Software Development Costs Impairment Charges SoftwareDevelopmentCostsImpairmentCharges	0	usd
CY2023Q1	SURG	Software Development Costs Impairment Charges SoftwareDevelopmentCostsImpairmentCharges	0	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31429135	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34776443	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	700000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	570000	usd
CY2022Q4	us-gaap	Investments Investments	354206	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	110203	usd
CY2023Q4	us-gaap	Investments Investments	464409	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	16153	usd
CY2024Q1	us-gaap	Investments Investments	480562	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	16153	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	33029	usd
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	16806	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	32336	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3740554	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5693295	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1224595	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4546341	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17693283	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14131276	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	984853	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	403946	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18678136	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14535222	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2024Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	41589	usd
CY2023Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	41589	usd
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zsgTy89Q05a1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zbMC3dq6Aysh">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations, stockholders’ equity, or cash flows.</span></p>
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1006286	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1006286	usd
CY2024Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	797580	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	727197	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	291458	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361841	usd
CY2024Q1	us-gaap	Depreciation Depreciation	70383	usd
CY2023Q1	us-gaap	Depreciation Depreciation	70383	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3790427	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3627050	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1963093	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2126470	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163377	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163377	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	490130	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	653507	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	653507	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	165949	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1963093	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	387180	usd
CY2023	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	281304	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	668484	usd
CY2024Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	668484	usd
CY2024Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	55707	usd
CY2023Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	32265	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	474846	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14323	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	460523	usd
CY2024Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	19750	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2870	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	477403	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1159478	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1689367	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1866288	usd
CY2024Q1	SURG	Long Term Debt Maturities Repayments Of Principal After Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearTwo	477403	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	5192536	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	420107	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	387869	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	436688	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	399413	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M7D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	23363	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10687	usd
CY2024Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	5506	usd
CY2023Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	5385	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	28868	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	16072	usd
CY2024Q1	SURG	Operating Cash Outflows From Operating Lease Obligation Payment OperatingCashOutflowsFromOperatingLeaseObligationPayment	28012	usd
CY2023Q1	SURG	Operating Cash Outflows From Operating Lease Obligation Payment OperatingCashOutflowsFromOperatingLeaseObligationPayment	9548	usd
CY2024Q1	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability	98638	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	84595	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	116211	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	65041	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	66625	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	61099	usd
CY2024Q1	SURG	Lessee Operating Lease Liability Payments Due After Four LesseeOperatingLeaseLiabilityPaymentsDueAfterFour	107265	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	500836	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	64148	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	436688	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94244	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	342444	usd
CY2023Q4	us-gaap	Settlement Assets Current SettlementAssetsCurrent	7500	usd
CY2021Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	73000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Voting at 1 vote per share
CY2024Q1	SURG	Common Stock Outstanding Percentage CommonStockOutstandingPercentage	0.10	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1400000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4900000	shares
CY2024Q1	SURG	Stock Issued During Period Value New Issues Stock Issued For Cash StockIssuedDuringPeriodValueNewIssuesStockIssuedForCash	17249994	usd
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.60
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1395000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	15854994	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	411740	usd
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	242615	shares
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1290024	usd
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedGrantsInPeriodGross	695000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.24
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	695000	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.24
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedGrantsInPeriodGross	600000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.60
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1295000	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.26
CY2024Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	6078549	usd
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAveragePeriod	P0Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6801	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y1M28D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableNumber	10203	shares
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageExercisePrice	16.00
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested And Non Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageRemainingContractualTerm	P4Y1M28D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	104272	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.45
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.53
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	121276	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	116174	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.43
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableNumber	5101	shares
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageExercisePrice	16.00
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested And Non Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageRemainingContractualTerm	P3Y1M28D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	121276	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.79
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M19D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	121276	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.79
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M19D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.06	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0388	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	10026387	usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	10026387	usd
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested	P0Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	43814	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	4.73
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	63325	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	26.39
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5574253	shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	4.81
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P0Y10M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	9348348	usd
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5574253	shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	4.81
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P0Y10M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	9348348	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1953308	shares
CY2024Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	4.73
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	1667	shares
CY2024Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	12.50
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3619278	shares
CY2024Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	4.85
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P0Y7M9D
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	3619278	shares
CY2024Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	4.85
CY2024Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P0Y7M9D
CY2024Q1	us-gaap	Revenues Revenues	31429135	usd
CY2023Q1	us-gaap	Revenues Revenues	34776443	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	23246468	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	27081960	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	6430806	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2989421	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1751861	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4705062	usd
CY2024Q1	us-gaap	Assets Assets	69585173	usd
CY2023Q4	us-gaap	Assets Assets	41925307	usd
CY2024Q1	us-gaap	Liabilities Liabilities	13399674	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13521843	usd
CY2024Q1	us-gaap	Assets Net AssetsNet	0	usd
CY2022	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	25000000	usd
CY2022	SURG	Sales Of Asset Description SalesOfAssetDescription	The agreement could be extended by a period of one (1) year upon mutual consent.
CY2022Q4	SURG	Sales Of Asset Percentage SalesOfAssetPercentage	0.0985	pure
CY2024Q1	SURG	Installment Sale Credit Description InstallmentSaleCreditDescription	3 month rolling average of 70% of the installment sale credit amount.
CY2024Q1	SURG	Prepayment Penalty Description PrepaymentPenaltyDescription	The Company was subject to a cancellation fee of 3% during the first year and 2% during the second year.
CY2024Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	2000	usd
CY2024Q1	SURG	Default Rate Description DefaultRateDescription	For any unpaid amounts under this agreement, the Company was subject to a fee of 1.35% per month (16.2% annualized).
CY2024Q1	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.02	pure
CY2024Q1	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	5000000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Commitment Fee Description LineOfCreditFacilityCommitmentFeeDescription	For example, if the initial installment sale credit amount is $15,000,000, the credit availability fee would be $300,000 (2%). Any subsequent increase of $5,000,000 or more would result in an additional fee of $100,000 (2%). Commitment fees are paid over a period of 12 months as part of the Seller’s monthly invoicing.
CY2023	us-gaap	Professional Fees ProfessionalFees	491536	usd
CY2024Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	130000	usd
CY2024Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	293000	usd
CY2024Q1	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	423000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1964	pure
CY2024Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	322000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	893000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.065	pure
CY2024Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	107000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	296000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	5000	usd
CY2024Q1	SURG	Income Tax Expense Benefit Subtotal IncomeTaxExpenseBenefitSubtotal	434000	usd
CY2023Q1	SURG	Income Tax Expense Benefit Subtotal IncomeTaxExpenseBenefitSubtotal	1189000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-11000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1189000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	423000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2586	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2024Q1	SURG	Reserve For Uncollectible Accounts ReserveForUncollectibleAccounts	5000	usd
CY2023Q4	SURG	Reserve For Uncollectible Accounts ReserveForUncollectibleAccounts	5000	usd
CY2024Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3157000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3844000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3537000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3849000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	779000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	790000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2758000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3059000	usd
CY2024Q1	SURG	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	67000	usd
CY2023Q4	SURG	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	224000	usd
CY2024Q1	SURG	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	149000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	216000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	224000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2542000	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2835000	usd
CY2024Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11000	usd

Files In Submission

Name	View Source	Status
0001493152-24-018890-index-headers.html	Edgar Link	pending
0001493152-24-018890-index.html	Edgar Link	pending
0001493152-24-018890.txt	Edgar Link	pending
0001493152-24-018890-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
surg-20240331.xsd	Edgar Link	pending
surg-20240331_def.xml	Edgar Link	unprocessable
surg-20240331_lab.xml	Edgar Link	unprocessable
surg-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
surg-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SURG
SurgePays, Inc. Stock $surg

2024 Q2 Form 10-Q Financial Statement

#000149315224018890 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG SurgePays, Inc. Stock $surg

2024 Q2 Form 10-Q Financial Statement

#000149315224018890 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG
SurgePays, Inc. Stock $surg